SCHEMBL3036715

SCHEMBL3036715

CCOC(=O)[C@H]1CC[C@]2(CC1)CN(c1ccccc1Cl)C(=O)O2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.48
NPY5R Q15761 1/20 0.47
TSHR P16473 4/20 0.47
ALDH1A1 P00352 4/20 0.47
GAA P10253 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.41
OPRM1 P35372 1/20 0.41
KCNH2 Q12809 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
ATM Q13315 1/20 0.41
LMNA P02545 1/20 0.41
NLRP3 Q96P20 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3026796 0.90 HSD11B1 (0.49) HSD11B1NPY5RALDH1A1MEN1KMT2A
SCHEMBL3028745 0.88 HTT (0.48) HSD11B1NPY5RTSHRALDH1A1MEN1
SCHEMBL13045573 0.88 HTT (0.48) HSD11B1NPY5RTSHRALDH1A1MEN1
SCHEMBL13045544 0.86 HSD11B1 (0.51) HSD11B1NPY5RALDH1A1MEN1KMT2A
SCHEMBL2998466 0.86 HSD11B1 (0.51) HSD11B1NPY5RALDH1A1MEN1KMT2A
SCHEMBL3021457 0.86 HSD11B1 (0.51) HSD11B1NPY5RALDH1A1MEN1KMT2A
SCHEMBL3030982 0.85 NPY5R (0.51) HSD11B1NPY5RALDH1A1GAAMEN1
SCHEMBL3028152 0.83 HSD11B1 (0.48) HSD11B1NPY5RKMT2AMAPTPOLB
SCHEMBL3669039 0.83 HSD11B1 (0.48) HSD11B1NPY5RKMT2AMAPTPOLB
SCHEMBL3032395 0.83 NPY5R (0.51) HSD11B1NPY5RALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216821-A1 Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists BARTON NICHOLAS PAUL 2010-08-26 US disclosed
US-20100216821-A1 Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists BARTON NICHOLAS PAUL 2010-08-26 US disclosed
US-20100216821-A1 Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists BARTON NICHOLAS PAUL 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216821-A1 Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists NPY5R, NPY4R, NPY1R HSD11B1 1359/4885NPY5R 1/4885TSHR 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.